Blau Farmaceutica 2Q26 net income drops 12% to BRL 56 million; revenue rises 5% to BRL 487 million

• Blau Farmacêutica posted 2Q26 net revenue of BRL 487 million, up 5% year over year.
• Net income fell 12% to BRL 56 million; recurring net income rose 12% to BRL 71 million.
• Recurring EBITDA climbed 3% to BRL 126 million; recurring EBITDA margin slipped 0.4 percentage points to 25.9%.
• Operating cash flow more than doubled to BRL 186 million; free cash flow to the firm swung to BRL 81 million.
• Management expects revenue to reaccelerate in the second half as new production lines start from 3Q26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blau Farmaceutica SA published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.